Effects of interferon-based therapies in functional cure and hepatocellular carcinoma risk reduction in patients with chronic hepatitis B: real-world evidence from 2-year data of OASIS project

被引：0
|
作者：
Zhang, Qiran [1 ]
Sun, Feng [1 ]
Yu, Yiqi [1 ]
Zhao, Tingting [1 ]
Sui, Shulan [1 ]
Zhang, Jiming [1 ]
Shang, Jia [2 ]
Geng, Jiawei [3 ]
He, Yignli [4 ]
Guo, Ying [5 ]
Zhao, Caiyan [6 ]
Zhu, Yueyong [7 ]
Yan, Xuebing [8 ]
Zhang, Wenhong [1 ]
机构：
[1] Fudan Univ, Huashan Hosp, Dept Infect Dis, Natl Med Ctr Infect Dis, Shanghai, Peoples R China
[2] Henan Prov Peoples Hosp, Dept Infect Dis, Zhengzhou, Peoples R China
[3] First Peoples Hosp Yunnan Prov, Dept Infect Dis, Kunming, Yunnan, Peoples R China
[4] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Infect Dis, Xian, Peoples R China
[5] Third Peoples Hosp Taiyuan, Dept Infect Dis, Taiyuan, Peoples R China
[6] Hebei Med Univ, Dept Infect Dis, Affiliated Hosp 3, Shijiazhuang, Hebei, Peoples R China
[7] Fujian Med Univ, Dept Infect Dis, Affiliated Hosp 1, Fuzhou, Peoples R China
[8] Xuzhou Med Univ, Dept Infect Dis, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-147
引用
收藏
页码：S1133 / S1134
页数：2
相关论文
共 24 条
  • [21] Aldo-keto reductase family 1 member B10 expression predicts the risk of hepatocellular carcinoma development in chronic hepatitis C patients who achieved sustained virological response to interferon-based anti-viral therapy
    Murata, Ayato
    Genda, Takuya
    Ichida, Takafumi
    Sato, Shunsuke
    Tsuzura, Hironori
    Narita, Yutaka
    Kanemitsu, Yoshio
    Ishikawa, Sachiko
    Kikuchi, Tetsu
    Mori, Masashi
    Hirano, Katsuharu
    Iijima, Katsuyori
    Wada, Ryo
    Watanabe, Sumio
    HEPATOLOGY, 2014, 60 : 1087A - 1087A
  • [22] Efficacy and prediction analysis of pegylated interferon alpha-2b in treatment-naive HBeAg negative chronic hepatitis B patients with normal ALT: a multicenter real-world study (Ice-breakting Project in China)-Interim analysis
    Zhang, Chong
    Zeng, Da-Wu
    Cai, Da-Chuan
    Xue, Xiu-Lan
    Zhang, Ling-Yi
    Song, Bao-Jun
    Gao, Yu-Feng
    Huang, Yan
    Shang, Jia
    Wu, Xiao-Feng
    Zhang, Ying
    Jin, Hua
    Chen, Hui
    Tang, Hong
    Lu, Xiaobo
    Guan, Yujuan
    Min, Feng
    Xu, Liang
    Li, Gang
    Wang, Zhen-Guang
    Dou, Xiaoguang
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1165 - S1166
  • [23] Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data
    Siriyotha, Sukanya
    Lukkunaprasit, Thitiya
    Looareesuwan, Panu
    Kunakorntham, Patratorn
    Anothaisintawee, Thunyarat
    Nimitphong, Hataikarn
    Mckay, Gareth J.
    Attia, John
    Thakkinstian, Ammarin
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4418 - 4428
  • [24] Outcome of treatment with peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB) in the real-world: interim analysis of data from the large European S-Collate cohort
    Marcellin, Patrick
    Curescu, Manuela G.
    Piekarska, Anna
    Mazur, Wlodzimierz W.
    Hezode, Christophe
    Guyader, Dominique
    Jochum, Christoph
    Foster, Graham R.
    Ouzan, Denis
    Cornberg, Markus
    Bogdan, Manfred
    Messinger, Diethelm
    Cartier, Veronique
    Petersen, Joerg
    HEPATOLOGY, 2013, 58 : 656A - 657A
123